RPRX Stock Summary and Trading Ideas (Royalty Pharma PLC - Class A | NASDAQ:RPRX)

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Royalty Pharma PLC - Class A trades on the NASDAQ stock market under the symbol RPRX.

As of June 8, 2026, RPRX stock price declined to $54.86 with 3,416,405 million shares trading.

RPRX has a beta of 0.43, meaning it tends to be less sensitive to market movements. RPRX has a correlation of 0.11 to the broad based SPY ETF.

RPRX has a market cap of $24.32 billion. This is considered a Large Cap stock.

Last quarter Royalty Pharma PLC - Class A reported $631 million in Revenue and $1.30 earnings per share. This fell short of revenue expectation by $-247 million and exceeded earnings estimates by $.11.

In the last 3 years, RPRX traded as high as $56.50 and as low as $24.05.

The top ETF exchange traded funds that RPRX belongs to (by Net Assets): VXF, VFLO, IWR, VYM, SCHM.

RPRX has outperformed the market in the last year with a price return of +65.2% while the SPY ETF gained +25.9%. RPRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +20.6% and +0.7%, respectively, while the SPY returned +8.8% and -0.9%, respectively.

RPRX support price is $54.96 and resistance is $56.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RPRX shares will trade within this expected range on the day.